James L. Gulley, MD, PhD

James L. Gulley, MD, PhD

James L. Gulley, MD, PhD

Chief, Genitourinary Malignancies Branch & Director, Medical Oncology Service, CCR; National Cancer Institute, National Institutes of Health

Dr. Gulley is an internationally recognized expert in immunotherapy for cancer who is in his 19th year at the National Institutes of Health. He serves within the Center for Cancer Research (CCR) of the National Cancer Institute, as Chief of the Genitourinary Malignancies Branch, Director of the Medical Oncology Service and Head of the Immunotherapy Section. He has been instrumental in the clinical development of Prostvac, an experimental prostate cancer vaccine developed within the CCR and is the principal investigator of the Prospect Trial, an international randomized phase 3 study of Prostvac which recently completed enrollment. He also has been instrumental in the development of avelumab, an anti-PDL1 antibody that the first-in-human study was done at the CCR and now has been given breakthrough designation by the FDA with multiple phase III studies ongoing or planned.

Dr. Gulley is most excited about the potential for combination therapy and has made significant contributions to combination therapy (therapeutic vaccine combined with each of the following: external beam radiation therapy, radionuclide, chemotherapy and most recently immune checkpoint modulation). The latter immune / immune combination therapy holds significant promise and Dr. Gulley is leading efforts to expand the clinical utility of immune checkpoint modulators into non-T-cell inflamed tumors through combination with therapeutic vaccines and other immunotherapies.

Dr. Gulley has received numerous awards including the 2010 Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the US government on outstanding scientists early in their careers. He has been an investigator on >100 trials, authored >200 scientific papers or chapters, and has made numerous presentations at national and international meetings.